Principal Medical Director of Global Drug Safety and Pharmacovigilance
Robert Allen, MD has more than 20 years of experience in the pharmaceutical industry, with extensive work in drug development for candidates in the neuroscience and pain therapeutic areas.
Robert Allen has worked in both large and small pharma and more recently has worked as CMO for 3 different start-up companies. He also has a broad range of regulatory submission experience, including INDs, NDAs, and sNDAs.
As Principal Medical Director of Global Drug Safety and Pharmacovigilance, Dr. Allen provides regulatory and medical guidance for the MMS global pharmacovigilance and drug safety teams, including medical monitoring and medical data review, safety surveillance and signal detection, aggregate level medical review and periodic safety reports, risk evaluation and mitigation strategies. In addition, Dr. Allen acts as senior technical reviewer for complex projects and advises sponsors on Drug development plans, submissions and medical affairs projects.
Dr. Allen has worked at Parke Davis, Pfizer, AstraZeneca, Wyeth Research, Premier CRO, Adolor, Centrexion, and Inventive / Syneos Health. He has also been CEO of Allen Medical LLC for over ten years, consulting and advising sponsors on clinical studies and drug development.
Prior to joining Industry, Dr Allen worked in the Neuro-Oncology department at MD Anderson Cancer Center, and in the Neurology Department and Pain Center at the University of California, San Francisco. He completed a Pain Fellowship at UCSF, a Neurology Residency at The University of Michigan, and an Internal Medicine Residency at Faulkner Hospital in Boston. He earned his MD at Tufts Medical School in Boston, Massachusetts and his Undergraduate degree at Boston College.
CONNECT WITH US